Drug intelligence / Profile preview

PRI-200

Development stage: Preclinical
Lead developer: Priavoid
Modality: Peptides, Small Molecules

Overview

PRI-200 is a synthetic D-peptide drug developed by Priavoid for the treatment of Alzheimer's disease and other tauopathies. It acts as an inhibitor of the microtubule-associated protein tau, targeting pathological aggregation of tau protein, which is implicated in neurodegenerative diseases such as Alzheimer's. The drug is classified as an antidementia agent and represents a new molecular entity currently in preclinical development[2][3].

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on PRI-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRI-200.

Explore the full profile